Sagent Pharma closes initial public offering of 5,750,000 shares of common stock

Sagent Pharmaceuticals, Inc. (the "Company") (Nasdaq: SGNT) today announced that it has closed its previously announced initial public offering of 5,750,000 shares of its common stock at a price to the public of $16.00 per share.  In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional 862,500 shares of common stock from the Company.  As a result, the total initial public offering size was 6,612,500 shares of common stock.

Morgan Stanley, BofA Merrill Lynch, and Jefferies acted as the joint bookrunners for the offering.  Needham & Company, LLC and RBC Capital Markets acted as the co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 19, 2011.  The offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by e-mail at [email protected]; from BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department, or by e-mail at [email protected]; or from Jefferies, 520 Madison Avenue, 12th Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340, or by e-mail at [email protected].

SOURCE Sagent Pharmaceuticals, Inc.